Fortress Biotech, Inc. Accrued Royalties, Current
Fortress Biotech, Inc. (FBIO) had Accrued Royalties, Current of $2.06 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Notes › Accrued Liabilities, Current
us-gaap:AccruedRoyaltiesCurrent · last filed 2026-08-13
- 2026-06-30: Accrued Royalties, Current $2.06M.
- 2026-03-31: Accrued Royalties, Current $1.86M.
- 2025-12-31: Accrued Royalties, Current $1.80M.
- 2025-09-30: Accrued Royalties, Current $2.09M.
| Period end | Accrued Royalties, Current |
|---|---|
| 2026-06-30 | $2.06M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $1.86M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $1.80M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $2.09M 10-Q · filed 2025-11-14 |
| 2025-06-30 | $1.77M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $1.41M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $1.37M 10-K · filed 2026-03-31 |
| 2024-09-30 | $1.60M 10-Q · filed 2024-11-14 |
| 2024-06-30 | $1.66M 10-Q · filed 2024-08-13 |
| 2024-03-31 | $1.38M 10-Q · filed 2024-05-15 |
| 2023-12-31 | $2.02M 10-K · filed 2025-03-31 |
| 2023-09-30 | $1.79M 10-Q · filed 2023-11-14 |
| 2023-06-30 | $2.20M 10-Q · filed 2023-08-14 |
| 2023-03-31 | $1.61M 10-Q · filed 2023-05-15 |
| 2022-12-31 | $2.63M 10-K · filed 2024-03-28 |
| 2022-09-30 | $2.58M 10-Q · filed 2022-11-14 |
| 2022-06-30 | $3.03M 10-Q · filed 2022-08-11 |
| 2022-03-31 | $3.78M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $3.83M 10-K · filed 2023-03-31 |
| 2021-09-30 | $4.50M 10-Q · filed 2021-11-15 |
| 2021-06-30 | $3.34M 10-Q · filed 2021-08-16 |
| 2021-03-31 | $2.05M 10-Q · filed 2021-05-17 |
| 2020-12-31 | $2.68M 10-K · filed 2022-03-28 |
| 2020-09-30 | $1.91M 10-Q · filed 2020-11-09 |
| 2020-06-30 | $1.80M 10-Q · filed 2020-08-10 |
| 2020-03-31 | $2.46M 10-Q · filed 2020-05-11 |
| 2019-12-31 | $2.32M 10-K/A · filed 2021-04-09 |
| 2019-09-30 | $1.83M 10-Q · filed 2019-11-12 |
| 2019-06-30 | $1.64M 10-Q · filed 2019-08-09 |
| 2019-03-31 | $1.23M 10-Q · filed 2019-05-10 |
| 2018-12-31 | $1.11M 10-K · filed 2020-03-16 |
| 2018-09-30 | $1.04M 10-Q · filed 2018-11-09 |
| 2018-06-30 | $1.27M 10-Q · filed 2018-08-09 |
| 2018-03-31 | $1.09M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $1.41M 10-K · filed 2019-03-18 |
| 2016-12-31 | $263.00K 10-K · filed 2018-03-16 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ALX ONCOLOGY HOLDINGS INC (ALXO) | United States | $0.187B | -3.52 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |